Skp2 Inhibitors: Novel Anticancer Strategies

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Skp2 (Skip complex-associated protein 2) is overexpressed in numerous human cancers.
• Skp2 is a key component of the SCFSkp2 ubiquitin E3 ligase complex, crucial for protein degradation.
• Its dysregulation contributes to tumorigenesis by affecting cell cycle and apoptosis pathways.

Purpose of the Study:

• To review the development of Skp2 inhibitors.
• To highlight diverse mechanisms of action for Skp2 inhibition in cancer therapy.

Main Methods:

• Review of scientific literature on Skp2 function and inhibition.
• Analysis of different classes of Skp2 inhibitors and their therapeutic potential.

Main Results:

• Skp2 promotes cancer by down-regulating tumor suppressors like p27, facilitating cell cycle progression.
• Skp2 inhibits apoptosis by interfering with p53 stabilization and acetylation.
• Various strategies targeting Skp2's proteolytic and non-proteolytic functions are under development.

Conclusions:

• Inhibition of Skp2, a critical factor in tumorigenesis, presents a promising anti-cancer therapeutic strategy.
• Targeting Skp2 offers a novel approach to combat various human cancers by restoring cell cycle control and promoting apoptosis.